Suggested Dosing
Congestive Heart Failure
2-6 g/day PO div BID-TID
Acute Hepatitis
4 g PO TID x 6 weeks
Treatment of Steatorrhea in Children with Cystic Fibrosis
30 mg/kg day x 4 months in addition to pancreatic enzyme supplementation
Cystathionine Beta-Synthase Deficient Homocystinuria (Orphan)
Indicated for treatment of cystathionine beta-synthase deficient homocystinuria
Orphan indication sponsor
- Johan L. Van Hove, MD, PhD; Department of Pediatrics/University of Colorado DE; 13121 E. 17th Ave; PO Box 6508; Aurora, CO 80045
Suggested Uses
CHF, hypertension, hypercholesterolemia, cystic fibrosis, antiatherogenic effects
Other uses include seizure disorders (epilepsy), autism, ADHD, retinal degeneration, diabetes, alcoholism, improve mental performance & antioxidant.
Efficacy
In human clinical studies taurine lowered blood pressure
CHF: Seems to improve left ventricular function in patients with New York Heart Association functional class II to IV
Acute Hepatitis: Might improve liver function
In animal studies taurine lowered lipid levels, but human studies are contradictory
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (35)
- aldesleukin
aldesleukin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- bicalutamide
bicalutamide decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- capecitabine
capecitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- cladribine
cladribine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- cytarabine
cytarabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- decitabine
decitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- docetaxel
docetaxel decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- floxuridine
floxuridine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- fludarabine
fludarabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- fluorouracil
fluorouracil decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- flutamide
flutamide decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- fulvestrant
fulvestrant decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- gemcitabine
gemcitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- goserelin
goserelin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- leuprolide
leuprolide decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- medroxyprogesterone
medroxyprogesterone decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- megestrol
megestrol decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- mercaptopurine
mercaptopurine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- nelarabine
nelarabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- nilutamide
nilutamide decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- oxaliplatin
oxaliplatin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- paclitaxel
paclitaxel decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- paclitaxel protein bound
paclitaxel protein bound decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- pegaspargase
pegaspargase decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown. Taurine was found to reduce platelet aggregation and may increase the risk of bleeding.
- pentostatin
pentostatin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- pralatrexate
pralatrexate decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- tamoxifen
tamoxifen decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- thioguanine
thioguanine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- toremifene
toremifene decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- treosulfan
treosulfan decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- triptorelin
triptorelin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- vinblastine
vinblastine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- vincristine
vincristine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- vincristine liposomal
vincristine liposomal decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
- vinorelbine
vinorelbine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.
Adverse Effects
None reported
Warnings
Contraindications
Hypersensitivity
Cautions
Pregnancy, lactation
Monitor pts with CHF
Pregnancy & Lactation
Pregnancy Category: avoid use
Lactation: avoid use
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: liver
Excretion: feces & urine
Mechanism of Action
Antioxidant, putative hypocholesterolemic, hypotensive, antiatherogenic & detoxifying activities
May also have steatorrhea-reducing activity in pts with cystic fibrosis & putative antidiabetic, inotropic & antiseizure activities